tbuckley/cabot-search huggingface dataset:
LCN2 and colon cancer — Have we hit the jackpot.
Authors: Vijay Kumar Srinivasalu, Nazia Chaudhary, Bhagyashree ., Nehanjali Dwivedi, Smitha P K, Rahul Thorat, Christopher Batulla, Sujan Kumar Dhar, Sorab N Dalal, Manjula Das
Journal: Journal of Clinical Oncology (2020)

e15608 Background: Lipocalin2 (LCN2, also known as neutrophil gelatinase-associated lipocalin) is a protein that in humans is encoded by the LCN2 gene. Its abnormal expression serves critical roles in EMT transition, angiogenesis, cell migration and invasion in many cancers. We aim to assess the in vitro and in vivo effects of LCN2 as a potential chemo and radiosensitizer. Methods: Normalized RNAseq RSEM values of LCN2 were compared between normal and tumour samples from TCGA. Differences between median expression levels were assessed using Wilcoxon rank sum test. Kaplan-Meier model was used for survival analysis. Immune cell population in publicly available Colon Adenocarcinoma dataset was estimated using MCP Counter tool. Cell systems used to experimentally study the role of LCN2 in therapy resistance and tumor progression were HCT116, HT29 and DLD1. PKP3 and/or LCN2 were knocked down by shRNA. Tumor regression and therapy (5FU and radiation) sensitivity upon Anti-LCN2 treatment were demonstrated in Xenograft mouse models. Results: Analysis of 23 TCGA datasets containing gene expression data for both tumour and adjacent normal samples indicated that LCN2 levels are elevated in colon tumors. Colon cancer cell line HCT116 derived PKP3 knock-down or LCN2 over-expressing cells showed therapy resistance. A comparison of the tumor cell lines HCT116, HT29 and DLD1 show that increased LCN2 expression correlates with therapy resistance. LCN2 levels correlated with resistance to 5FU (p = 0.006) and its ability to clear ROS (p &lt; 0.05) in vitro. Inhibiting LCN2 led to a decrease in invasion in vitro (p = 0.0005), increased sensitivity to 5FU in vitro (p = 0.001) and inhibition in tumor growth and increased sensitivity to 5FU and radiation (p = 0.005) in xenograft mouse models. On MCP counter analysis of TCGA, in Colon adenoca the normal samples show a correlation between LCN2 expression and T-cells (Pearson r = 0.45, p = 0.0028) and with the T-cell chemoattractant CXCL10 (Pearson r = 0.5, p &lt; 0.0001). Such correlations are broken in tumour samples. Conclusions: LCN2 expression leads to chemo and radio resistance in colon cancer cell lines and xenograft mouse models. Inhibiting LCN2 function can inhibit tumor progression and sensitizes tumors to radiation and 5FU. These results suggest that LCN2 expression could be a marker that can be used to determine the choice of therapy offered to patients and that LCN2 could serve as a therapeutic target that sensitizes cells to radio and chemotherapy. LCN2 affects tumor progression and therapy sensitivity probably through T cell mediated immune pathway.
Characterization of mutations in HRR genes, TMB, and PD-L1 expression in Chinese patients with ovarian cancer.
Authors: Hong Zheng, Min Gao, Weijiao Gao, Nan Zhang, Hongguo Wang, Nan Song, Naiyi Zhang, Wei Wang, Qian Li, Mingming Yuan, Rongrong Chen, Yunong Gao
Journal: Journal of Clinical Oncology (2020)

e18048 Background: A great number of clinical studies have confirmed the promising efficacy of ICIs and PARPi in multiple solid tumors. Here we aim to investigate the biomarkers related to these emerging therapies, including mutations in DNA homologous recombination repair (HRR) genes, tumor mutation burden (TMB) and PD-L1 expression in Chinese patients (pts) with ovarian cancer. Methods: A total of 209 pts with ovarian cancer were enrolled. Matched tumor-normal NGS of 1021 cancer-related genes was performed in 98 pts (T: 71 pts, T+B: 25 pts, B: 2 pts). Germline variants in ovarian cancer susceptibility genes were analyzed in 209 pts. PD-L1 expression was assessed by immunohistochemistry (Dako 22C3). Pts with TPS≥50 were considered as high expression and pts with 1≤TPS&lt;50 was considered as expression. Tissue TMB was calculated as the number of somatic non-synonymous SNVs and Indels per Mb in the coding region (with VAF ≥0.03). The threshold of TMB-high was 5.76 muts/MB. Results: Germline pathogenetic or likely pathogenetic variants were identified in 28.7% of pts ( BRCA1 15.3%, BRCA2 7.7%, RAD51D 2.0%, PALB2 1.0%, and 0.7% for CHEK2, MSH2, RAD51C and MSH6). Germline variants in HRR genes was identified in 27.3% of pts. The mutation detection rates in 96 tissue samples from surgery or biopsy and 25 ctDNA samples collected at disease recurrence were 100% and 96%, respectively. An average of 34.6% of tissue-derived mutations can be identified in ctDNA, and 55.2% of tissue-derived actionable mutations were observed in ctDNA. Besides, there were 83 private mutations, including PPMID (5), ARID2 (3), CHEK2 (3), PIK3CA (3) and ARID1B (2). Mutations in HRR genes were found in 36.5% (35/96) of tissue samples, and 12 pts harbored more than one HRR mutations. The detection rate of HRR mutations in ctDNA was 40% (10/25), and cases harbored more than one HRR mutations. The status of TMB and PD-L1 was analyzed in 30 pts. Two pts were evaluated as PD-L1 highly expressed and 9 pts were considered as expressed. Eight pts were assessed as TMB-high. Five pts with PD-L1 negative expression were TMB-high, and 8 pts with TMB-low were PD-L1 positive expression. TMB and PD-L1 expression are independent indicators with the spearman r of 0.01 (p = 0.96). Conclusions: The detection rate of germline and somatic mutations in HRR genes were 27.3% and 36.5-40%, respectively, which defined a large number of ovarian cancer pts who can benefit from PARPi. PD-L1 expression and TMB are independent biomarkers, which may be combined to predict the efficacy of immunotherapy in future exploratory trials.
Clinical analysis of 5 cases of atypical pulmonary carcinoid
Authors: Lei Wang, Maoling Yuan, Yan Peng, Pengyi Yu, Qianyun Wang, Zhonglin Wang
Journal: BMJ (2016)

回顾分析2000年1月至2015年12月诊治、病理确诊的5例不典型类癌患者的临床资料。5例中，男2例，女3例，年龄39～76岁；体检发现2例，刺激性干咳2例，胸痛1例，咯血1例，痰中带血1例，均无类癌综合征表现。血癌胚抗原水平偏高1例；CT检查均提示占位病变；痰细胞学检查均阴性；4例行纤维支气管镜检查阳性。均行手术治疗，2例辅以化疗。术后随访24～58个月，1例术后1年发现前列腺癌骨转移，带瘤生存，4例无瘤生存。提示，肺不典型类癌临床少见，术前诊断较为困难，术后病理是确诊的主要方法，手术是治疗肺不典型类癌的有效方法，术后需要长期随访。
Common problems and treatment of menopausal hormone therapy
Authors: Xia Liu
Journal: BMJ (2016)

绝经相关激素治疗(MHT)对围绝经期和绝经后妇女的健康益处已经得到公认，并被越来越多的女性所接受，但MHT也会带来一系列困惑和问题。全科医生应了解熟悉MHT的利弊，正确掌握处理MHT常见问题的方法，才能对患者做出正确的指导和决策。
Treatment patterns and outcomes of patients with penile squamous-cell carcinoma (PSCC) undergoing inguinal lymph node dissection (ILND): An analysis of a multicenter contemporary database.
Authors: Marco Bandini, Yao Zhu, Dingwei Ye, Antonio Augusto Ornellas, Nick Watkin, Michael Ager, Oliver W. Hakenberg, Axel Heidenreich, Daniele Raggi, Friederike Haidl, Laura Marandino, Filippo Pederzoli, Alberto Briganti, Francesco Montorsi, Juan Chipollini, Mounsif Azizi, Maarten Albersen, Philippe E. Spiess, Andrea Necchi
Journal: Journal of Clinical Oncology (2020)

5585 Background: PSCC is a rare tumor and the administration of guidelines-based therapies is still problematic in real-world practice. Survival outcomes remain suboptimal in patients (pts) with ILN involvement. Multinational analyses of real-world patterns are needed. Methods: Within an international, multicenter database of 965 PSCC pts who received ILND from 1980-2019, 630 had complete information for the variables of interest, from USA (N=81), Europe (EU, N=355), South America (SA, N=90), and China (Ch, N=104). Descriptive analyses according to geographical and ethnicity/race distribution were made. Comparisons of outcomes were made with Kaplan-Meier analyses and corresponding logrank tests. Results: Median age at diagnosis was 59 yrs, with no differences worldwide and according to ethnicity/race. Pts from SA presented with more advanced cT-stage (cT3-4: 26.7% vs. 17.3% USA vs. 7.6% EU) while EU pts presented with more advanced cN-stage (cN3: 14.9% vs. 11% USA vs. 7.8% SA vs. 5.8% Ch) as well as pathological (p)N-stage: pN3 pts were 53% in EU, 33.3% in USA, 20% in SA, and 18.3% in Ch. Perioperative chemotherapy (pCT) was more frequently administered in EU (53.8%) vs. USA (34.6%) SA (5.6%) Ch (7.7%). cT-stage was more frequently advanced in black pts (cT3-4: 33.3% vs. 12% Caucasian, 6.2% Hispanic/latino, 0% Asian) and the same was for cN-stage (cN3: 25% in black, 13% in Caucasian, 6.2% in Hispanic/latino, 6% in Asian). Conversely, pN3 pts were more frequently Caucasian (45.6%) vs. black (25%), Hispanic/latino (19%), and Asian (18%). pCT was more frequently administered in Caucasian pts (45%) vs. black (8.3%), Hispanic/latino (0), and Asian (8%). No significant differences in overall survival (OS) were observed according to geographical region or ethnicity/race, in the total pts and in the subgroups according to cT, cN, pN-stages and pCT. Median OS after pCT and ILND was 95 months. Bilateral ILN involvement was equally observed regardless of geographical region and ethnicity/race. In the total population, pCT significantly prolonged OS in pts with bilateral ILN (p=0.04), but not in pts with pelvic LN. Conclusions: Treatment patterns for PSCC undergoing ILND remain heterogeneous worldwide, and adherence to guidelines is seemingly poor. However, long-term outcomes with pCT remain uniformly suboptimal with &lt;50% pts alive at 10 yrs. Further collaborative efforts are needed in this orphan disease to harmonize the therapeutic paradigm.
Real-world treatment patterns and clinical outcomes in <i>EGFR</i>-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients.
Authors: Nan Bi, Luhua Wang, Kunpeng Xu, Hong Ge, Mingyan E, Li Zhang, Jianzhong Cao, Xu Zhang, Bing Xia, Lujun Zhao, Jiancheng Li, Chen Hu
Journal: Journal of Clinical Oncology (2020)

9047 Background: The chemoradiation therapy (CRT) is the standard care for unresectable LA-NSCLC. The addition of EGFR-TKIs in first-line treatment of EGFR-mutant subpopulation is debatable. Methods: We retrospectively collected data for patients with unresectable stage III NSCLC harboring EGFR mutations from nine major academic cancer institutions in China from Jan 2012 to December 2018. Patients with ALK rearrangements were excluded. Patients were categorized into three subgroups according to the primary treatment: 1) RT+TKI: Combined RT and EGFR-TKI with/out chemotherapy; 2) no TKI: CRT alone; 3) upfront TKI: EGFR-TKI followed by RT at local-regional progression. PFS and OS were calculated from the date of diagnosis. Log-rank test was used to assess for differences and Cox proportional hazards model was used to adjust for covariates. Results: A total of 367 patients met selection criteria were included in the study. Patients receiving TKI were older (≥60 years: 54.7% TKI v 36.4% and RT+TKI 33.3% CRT; P = 0.001), and more patients receiving CRT had uncommon EGFR mutations ( 10.3% CRT v 2.3% RT+TKI and 4.0% TKI; P = 0.020). Other baseline characteristics were well balanced among groups. With a median follow-up of 40.8 months, the median PFS and OS were 16.6 and 55.4 months for the entire cohort. The median PFS and OS for the three subgroups were shown in the table. On multivariable analysis, after adjusting for age, KPS status, smoking status, stage, and type of EGFR mutations, TKI+RT was independently associated with improved PFS (HR, 0.57; 95% CI, 0.41 to 0.78 ) and OS (HR, 0.61; 95% CI, 0.39 to 0.97) relative to upfront TKI; TKI+RT was also associated with improved PFS (HR, 0.38; 95% CI, 0.27 to 0.54 ) relative to CRT, but not OS (HR, 0.66; 95% CI, 0.40 to 1.11). Conclusions: The use of upfront EGFR-TKI with deferred RT at progression was associated with inferior OS in patients with EGFR-mutant unresectable LA-NSCLC. First-line use of radiotherapy and EGFR-TKI was associated with the longest PFS and OS, which requires further prospective, randomized evaluation. [Table: see text]
反复胸痛伴ST段压低一例
Authors: 杨国军, 任光圆
Journal: BMJ (2006)

患者男,38岁,农民.因反复胸痛3个月于2005年5月21日入院.患者3个月前无诱因渐出现胸骨后疼痛,呈阵发性闷痛,静息、活动、进食后均可发作,持续1 min～1 h不等,程度中等,向两侧肩背部放散,休息或诱发呕吐出少许胃内容物后可缓解,伴胸闷,无气急、咯血、咳嗽、咳痰,无发热、恶心呕吐、反酸嗳气、腹痛腹泻及其他不适,在外院以冠心病心绞痛治疗无好转而转入本院。
阿奇霉素应用中的相关问题
Authors: 张永信, 龙丰
Journal: BMJ (2005)

结合吴兴田和胡秋霞医生的问题谈谈阿奇霉素应用问题. 1.根据我国对抗生素的管理有关条例,进口抗生素都必须按规定在国内完成相应的Ⅰ期至Ⅳ期的临床药理试验,阿奇霉素同样经历了上述过程才能用于临床治疗。
Abstract 14733: Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality: The Lifetime Risk Pooling Project
Authors: Victor W Zhong, Linda Van Horn, Marilyn C Cornelis, John T Wilkins, Hongyan Ning, Mercedes R Carnethon, Philip Greenland, Robert J Mentz, Katherine L Tucker, Arnita F Norwood, Donald M Lloyd-Jones, Norrina B Allen
Journal: Circulation (2018)

Introduction: Whether dietary cholesterol and/or egg consumption are associated with cardiovascular disease (CVD) and mortality has been debated for decades. The 2015 Dietary Guidelines for America...
城市社区冠心病双向转诊实施情况分析
Authors: 严春泽
Journal: BMJ (2006)

由复兴医院心内科专科医生和社区全科医生共同协商制订冠心病双向转诊标准和实施办法,在复兴医院下属社区卫生服务站与复兴医院急诊和心内科门诊、病房及监护室间实施.研究期内,社区卫生服务站需转出的冠心病患者共94例,69例双向转诊成功,双向转诊成功率73.4%,转诊符合率95.5%,同时缩短了患者就诊时间和病情延误时间。
Comorbidities and survival in breast cancer: A retrospective cohort study from an academic institution in southern Illinois.
Authors: Ruby Maini, Manjari Rani Regmi, Priyanka Parajuli, Odalys Estefania Lara Garcia, Asad Cheema, Hamsa Sahib, Nitin Tandan, Cameron Koester, Noupama Mirihagalle, Sabree Abedrabo, Zurain Niaz, Abdisamad M. Ibrahim, Bishal Bhandari, Alexander Johnson, Kristin Delfino, Kathy Robinson, Abhishek Kulkarni, Meghna R. Desai
Journal: Journal of Clinical Oncology (2020)

e13624 Background: Breast cancer is the most common malignancy in females. Early detection and advances in treatment modalities have resulted in decreasing rates of breast cancer related death. While breast cancer survival has improved, risks of death from cardiovascular comorbidities have increased. Our study aims to evaluate survival among breast cancer patients with cardiac comorbidities. Methods: This study was conducted using a retrospective cohort design with use of de-identified hospital electronic patient records. ICD diagnoses codes were used to identify breast cancer patients. Our initial search criteria revealed 1618 patients. Our eligibility criteria included adult patients 18 years and older with newly diagnosed breast cancer from January 1 st , 2014 – January 31 st , 2017 which yielded 478 patients. All data was collected through retrospective chart review. Analysis was performed with SAS v9.4 software. Qualitative variables were analyzed using Chi-Square Test. Survival curves are estimated using Kaplan-Meier methodology and analyzed with a log rank test. Predictors of survival are assessed with Cox proportional hazards regression analyses. All significance was assumed at the p &lt; 0.05 level and reported as hazard ratios (HR). Results: Of our 478 patients, the following comorbidities were noted: diabetes n = 98 (21.17%), myocardial infarction (MI) n = 14 (2.98%), heart failure (HF) n = 36 (8.38%), coronary artery disease (CAD) n = 26 (5.75%), hypertension (HTN) n = 261 (55.77%), peripheral vascular disease (PVD) n = 9 (1.95%), hyperlipidemia (HLD) n = 230 (49.15%). Survival analysis was completed on patients with CAD (p = 0.49), HLD (p = 0.40), HTN (p = 0.15), MI (p = 0.52), and HF HR = 6.35 (95% CI 2.40-16.7, p = 0.0002). Pre-existing HF had a higher risk of mortality, which was statistically significant; however, all other single comorbidities were not. Overall survival (OS) in patients with more than one comorbidity HR = 1.36 (1.08-1.69, p = 0.006), was statistically significant. Conclusions: Patients with only one comorbidity be it MI, CAD, HTN, HLD did not have statistically significant results in OS. However, breast cancer patients with pre-existing HF are at 6.35-fold higher risk of mortality than those without HF. Patients with more than one comorbidity listed above were at 1.36-fold higher risk of mortality. Our results indicate that risk factor reduction may help improve survival in patients with breast cancer. Prospective validation of these findings is warranted.
PDL1 expression predicts therapeutic outcome in non metastatic anal squamous cell carcinoma (NMASCC).
Authors: Ilma Soledad Iseas, Mariano Golubicki, Juan Robbio, Gonzalo Ruiz, Ruben Salanova, Javier Mariani, Ezequiel Slutsky, Daniela Vecchioni, Ana Oviedo, Florencia Guerra, Julian Maquieira, Jorge Basilletti, Alejandra Picconi, Enrique Roca, Guillermo Mendez, Mariana Coraglio
Journal: Journal of Clinical Oncology (2020)

4054 Background: NMASCC is a rising incidence disease with up to 30% of treatment failure to achieve complete response (CR) after standard chemoradiotherapy (CRT) leading to severe morbidity and death. Stage III-TNM, p53 mutations, HPV negativity, HIV infection are linked to treatment failure. We investigated the predictive/prognostic role of TNM, CR, HPV, PDL1 positivity and CD3/CD8 densities in NM-ASCC from a single institution. Methods: All 79 eligible consecutive NMASCC pts (available FFPE pre-treatment samples) seen from October-2009 to April-2019 having completed definitive CRT (50.4 Gy Pelvic Radiotherapy with Mitomycin-C 12mg/m2/IV/d1-5 / FU 1000mg/m2/d1-4 d29-32 (28%), Mitomycin-C/Capecitabine 825 mg/m2/bid (38%), Cisplatin 60 mg/m2/IV d1-29 and 5FU (34%) were analyzed. Mean age: 59 (range 26-87), 72% female, Stage III: 59%, HPV positive: 86% (HPV-16: 80%);14% HIV positive. IHC assessed by two pathologist for PD-L1 expression (ClonSP263) and CD3-CD8+ TILS densities (Clone 2GV6, Clone SP57). HPV-DNA assessed by PCR (BSGP5+/6+ multiplexed with beta-globin). Kaplan-Meier survival, CR, DFS, OS and Univariate analyses were performed using Cox proportional hazard model. Results: CR achieved within 6 months of treatment completion was 68%( 53pts). Median follow-up after treatment completion: 35 months (range 6 –149). As of February 2020, 82% (65 pts) are alive, no evidence of disease:(57%) 46 pts, recurrence rate: 26%(22 pts), cancer death: 18% (14 pts). PDL1+ tumors ( &gt; 1% positivity-CPS score): 56%, expression levels: 1-5% (57%,26p), &gt; 10%-100% (43%,19p). PDL1+ had a strong association with CR (p = 0.021); higher PDL1+ levels had 8-fold of CR-likelihood than PDL1 negative.(OR 8.50 vs. 1.12). Significative Spearman correlation between PDL1 tumors with CR and CD3-CD8 TILS density was observed (R = 0.43,p = 0.0017 and R = 0.36,p = 0.00094 respectively), albeit CD3-CD8 failed to reach significance as prognostic factors for either CR, DFS or OS. Only CR and PDL1 positive were strongly significantly associated to DFS (HR 0.10 [IC 95% 0.04-0.28] p &lt; 0.001 and HR 0.28 [IC 95% 0.11-0.73] p = 0.006) and OS (HR 0.12 [IC 95% 0.03-0.45] p &lt; 0.001 and HR 0.15 [IC 95% 0.03-0.68] p &lt; 0.004). Low prevalence of HPV negative, early tumors, HIV positive cases in our series probably impacted in statistical power for prognosis correlation. Conclusions: PDL1 positivity was the strongest predictive/prognostic factor in NM-ASCC. Alternative therapeutics options to standard CRT should be explored on poor-risk patients as HPV-negative, P53-mutated and PDL1 negative patients.
Evaluation of a regularly updated knowledge base for curation of somatic mutations detected in whole exomes of melanoma and lung, colorectal, and breast cancers.
Authors: Stephanie J. Yaung, Jian Li, Adeline Pek, Lili Niu, John F. Palma, Maximilian Schmid
Journal: Journal of Clinical Oncology (2020)

e14072 Background: Evolving medical guidelines and complex multi-variant data from next-generation sequencing (NGS) testing of cancer samples make routine clinical interpretation of somatic variants challenging. We assessed the ability of NAVIFY(R) Mutation Profiler*, a CE-IVD somatic variant interpretation tool, to yield accurate time- and geography-specific clinical content on 2511 samples from The Cancer Genome Atlas (TCGA) across six solid tumor types. Methods: Whole exomes from lung adenocarcinoma (n = 469), lung squamous cell carcinoma (n = 325), colon adenocarcinoma (n = 368), rectum adenocarcinoma (n = 149), breast invasive carcinoma (n = 806), and skin cutaneous melanoma (n = 394) cases were analyzed. We utilized TCGA data from the Multi-Center Mutation Calling in Multiple Cancers (MC3) project to obtain consensus calling results of single nucleotide variants and indels. The open-access Mutation Annotation Format (MAF) file (v0.2.8) that stores variant calls was lifted to human reference genome GRCh38 and converted to individual Variant Call Format (VCF) files per case. VCF files were uploaded to NAVIFY Mutation Profiler to interpret actionable mutations according to a highly curated and up-to-date knowledge base (Roche Content v2.13.0 released December 6, 2019). We further assessed the accuracy of interpreting co-occurrences of actionable mutations. Results: Over 1.24 million somatic mutations across 20,590 genes were assessed with NAVIFY Mutation Profiler, which reported tier classifications of variants based on consensus recommendations from AMP, ASCO, CAP, and ACMG. 86% of cases had variants of strong (Tier I-A or I-B) or potential (Tier II-C or II-D) clinical significance; 56% of these cases had Tier I classifications, supported by robust clinical evidence. Potentially actionable variant-variant interactions were found in 14% of cases. The tool also identified appropriate tier classifications by geographic region in accordance with local medical guidelines. Conclusions: To benchmark against other tools, we utilized available exome data from TCGA MC3 to assess NAVIFY Mutation Profiler. While this study likely underestimates the fraction of cases with actionable mutations, given that copy number alterations or rearrangements are also present in TCGA samples, we found a higher yield of potentially actionable annotation than other published methods. * This product has not been evaluated by the Food and Drug Administration and is not commercially available in the United States.
The impact of weight loss on physical function in overweight or obese breast cancer survivors.
Authors: Jennifer Y. Sheng, Cesar Augusto Santa-Maria, Amanda L. Blackford, David Lim, Ashley Carpenter, Karen L. Smith, Gary Irvin Cohen, Janelle Coughlin, Lawrence J Appel, Vered Stearns, Claire Frances Snyder
Journal: Journal of Clinical Oncology (2020)

12053 Background: In the prospective POWER-remote trial, 51% and 12% of overweight/obese breast cancer survivors randomized to either a remotely delivered behavioral intervention or self-directed approach, respectively, lost ≥5% of baseline weight. We collected patient-reported outcomes (PROs) to examine the impact of &gt;5% weight loss on symptoms, physical function (PF), and wellbeing. We hypothesized a priori that, regardless of study arm, those with ≥5% weight loss would have improved PF at 6 months v. those who did not. Methods: Women with stage 0-III breast cancer, who completed local therapy and chemotherapy, with a BMI ≥25 kg/m 2 were randomized to the 12-month intervention or self-directed weight loss. POWER-remote consists of telephone coaching and online tracking of diet, activity and weight. Women in the self-directed arm received a lifestyle booklet. All women completed PROs at baseline, 6 and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. PROs were summarized descriptively and changes within and between groups were tested with multivariable mixed effects models, adjusted for age and baseline weight. Results: From 2013-2015, 96 women enrolled; 83 were evaluable at 6 months. At 6 months, PF scores improved in those with ≥5% weight loss v. not. While endocrine symptoms, fatigue, and anxiety improved in the group who lost ≥5%, differences between groups were not statistically significant. There was no significant change in sexual function, depression, or sleep within or between groups. Similar findings were seen across domains at 12 months, except pain improved in the group losing ≥5%. Conclusions: For overweight/obese breast cancer survivors, PF and other PROs improved among patients who lost ≥5%. These results support the patient-centered benefits of weight loss in this population. Clinical trial information: NCT01871116 . [Table: see text]